{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:50:28Z","timestamp":1791575428575,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"DOI":"10.1007\/s11739-026-04556-y","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:09:54Z","timestamp":1791569394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Apixaban vs rivaroxaban for venous thromboembolism: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1115-4610","authenticated-orcid":false,"given":"Bassel","family":"Alrabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwaleed Emad","family":"Alshakhshir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad S.","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Bandak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"4556_CR1","doi-asserted-by":"publisher","first-page":"1738139","DOI":"10.3389\/fcvm.2025.1738139","volume":"12","author":"L Alfehaid","year":"2025","unstructured":"Alfehaid L, Alsuhebany N, Tawfik YMK, Alowais SA, Adnan S, Alfriah J, Alabdelmuhsin L, Alshehri AM, Alyami M (2025) A comprehensive review of venous thromboembolism risk assessment models for hospitalized medical patients: comparative evidence, implementation challenges, and future directions. Front Cardiovasc Med 12:1738139","journal-title":"Front Cardiovasc Med"},{"key":"4556_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2023.100132","volume":"10","author":"SK Br\u00e6kkan","year":"2023","unstructured":"Br\u00e6kkan SK, Hansen J-B (2023) VTE epidemiology and challenges for VTE prevention at the population level. Thromb Update 10:100132","journal-title":"Thromb Update"},{"issue":"4","key":"4556_CR3","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.3390\/ijms24043169","volume":"24","author":"D Pastori","year":"2023","unstructured":"Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, Fallarino A, Corso C, Valeriani E, Menichelli D, Pignatelli P (2023) A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int J Mol Sci 24(4):3169","journal-title":"Int J Mol Sci"},{"key":"4556_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","volume":"398","author":"F Khan","year":"2021","unstructured":"Khan F, Tritschler T, Kahn SR, Rodger MA (2021) Venous thromboembolism. Lancet (London, England) 398:64\u201377","journal-title":"Lancet (London, England)"},{"issue":"21","key":"4556_CR5","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.3390\/jcm14217668","volume":"14","author":"W Bedrouni","year":"2025","unstructured":"Bedrouni W, Bedrouni M, Douketis J (2025) New Horizons in Venous Thromboembolism Management: a narrative review. J Clin Med 14(21):7668","journal-title":"J Clin Med"},{"issue":"8","key":"4556_CR6","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.3390\/jcm9082467","volume":"9","author":"M Nicholson","year":"2020","unstructured":"Nicholson M, Chan N, Bhagirath V, Ginsberg J (2020) Prevention of venous thromboembolism in and beyond. J Clin Med 9(8):2467","journal-title":"J Clin Med"},{"key":"4556_CR7","doi-asserted-by":"publisher","first-page":"101714","DOI":"10.1016\/j.jacadv.2025.101714","volume":"4","author":"JK Schaefer","year":"2025","unstructured":"Schaefer JK, Errickson J, Kong X, Ali MA, Chipalkatti N, Haymart B, Kaatz S, Krol GD, Sood SL, Froehlich JB, Barnes GD (2025) JACC Adv 4:101714","journal-title":"JACC Adv"},{"key":"4556_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1111\/jth.14239","volume":"16","author":"SK Br\u00e6kkan","year":"2018","unstructured":"Br\u00e6kkan SK, Hansen J-B (2018) Substantial recurrence risk after venous thromboembolism provoked by minor risk factors. J Thromb Haemost 16:1671\u20131673","journal-title":"J Thromb Haemost"},{"issue":"1","key":"4556_CR9","first-page":"391734","volume":"2012","author":"G Palareti","year":"2012","unstructured":"Palareti G (2012) Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) 2012(1):391734","journal-title":"Scientifica (Cairo)"},{"key":"4556_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.103317","volume":"10","author":"L Eischer","year":"2026","unstructured":"Eischer L, Kyrle PA, Kaider A, Schmidt A, Wildner B, Boc A, Bradbury C, Undas A, Couturaud F, Di Minno MND, Geersing G-J, Jimenez D, Parpia S, Palareti G, Poli D, Potaczek DP, Prandoni P, Schulman S, van Hylckama VA, Zabczyk M et al (2026) The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis. Res Pract Thromb Haemost 10:103317","journal-title":"Res Pract Thromb Haemost"},{"key":"4556_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol England 12:464\u2013474","journal-title":"Nat Rev Cardiol England"},{"issue":"4","key":"4556_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/jcm15041509","volume":"15","author":"P Leung","year":"2026","unstructured":"Leung P, Ho P, Lim HY (2026) Contemporary challenges in venous thromboembolism: evolving populations and implications for management and risk stratification. J Clin Med 15(4):1509","journal-title":"J Clin Med"},{"key":"4556_CR13","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2352-3026(18)30191-1","volume":"6","author":"GK Dawwas","year":"2019","unstructured":"Dawwas GK, Brown J, Dietrich E, Park H (2019) Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol England 6:e20\u2013e28","journal-title":"Lancet Haematol England"},{"key":"4556_CR14","first-page":"2142","volume":"48","author":"CI Coleman","year":"2017","unstructured":"Coleman CI, Peacock WF, Bunz TJ, Alberts MJ (2017) Effectiveness and safety of Apixaban, Dabigatran, and Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous Stroke or transient ischemic attack. Stroke United States 48:2142\u20132149","journal-title":"Stroke United States"},{"key":"4556_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1161\/ATVBAHA.108.162677","volume":"28","author":"PL Gross","year":"2008","unstructured":"Gross PL, Weitz JI (2008) New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 28:380\u2013386","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4556_CR16","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/a-1731-3922","volume":"122","author":"L Bertoletti","year":"2022","unstructured":"Bertoletti L, Gusto G, Khachatryan A, Quignot N, Chaves J, Moniot A, Mokgokong R (2022) Effectiveness and Safety of oral anticoagulants in the treatment of acute venous thromboembolism: a nationwide comparative cohort study in France. Thromb Haemost Germany 122:1384\u20131396","journal-title":"Thromb Haemost Germany"},{"key":"4556_CR17","first-page":"824","volume":"43","author":"L Girardi","year":"2023","unstructured":"Girardi L, Wang T-F, Ageno W, Carrier M (2023) Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism. Arterioscler Thromb Vasc Biol American Heart Association 43:824\u2013831","journal-title":"Arterioscler Thromb Vasc Biol American Heart Association"},{"key":"4556_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang T-F, Yeo E, Zhang G, Zwicker JI, Weitz JI, B\u00fcller HR (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med United States 378:615\u2013624","journal-title":"N Engl J Med United States"},{"key":"4556_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv United States 5:927\u2013974","journal-title":"Blood Adv United States"},{"key":"4556_CR20","doi-asserted-by":"publisher","first-page":"e1004754","DOI":"10.1371\/journal.pmed.1004754","volume":"22","author":"J Sun","year":"2025","unstructured":"Sun J, Mehta HB, Segal JB, Alexander GC (2025) Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: a retrospective cohort study. PLoS Med 22:e1004754","journal-title":"PLoS Med"},{"key":"4556_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MBC.0000000000000800","volume":"30","author":"AT Cohen","year":"2019","unstructured":"Cohen AT, Bauersachs R (2019) Rivaroxaban and the EINSTEIN clinical trial programme. Blood Coagul fibrinolysis an Int J Haemost Thromb England 30:85\u201395","journal-title":"Blood Coagul fibrinolysis an Int J Haemost Thromb England"},{"key":"4556_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med United States 369:799\u2013808","journal-title":"N Engl J Med United States"},{"key":"4556_CR23","first-page":"60","volume":"48","author":"R Bonar","year":"2016","unstructured":"Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K (2016) The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology England 48:60\u201371","journal-title":"Pathology England"},{"key":"4556_CR24","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/j.1538-7836.2006.01830.x","volume":"4","author":"WR Gould","year":"2006","unstructured":"Gould WR, Mcclanahan TB, Welch KM, Baxi SM, Saiya\u2010Cork K, Chi L, Johnson TR, Leadley RJ (2006) Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro. J Thromb Haemost 4:834\u2013841","journal-title":"J Thromb Haemost"},{"key":"4556_CR25","first-page":"179","volume":"6","author":"C Frost","year":"2014","unstructured":"Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F (2014) A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol Adv Appl 6:179\u2013187","journal-title":"Clin Pharmacol Adv Appl"},{"key":"4556_CR26","first-page":"S24","volume":"29","author":"IY Gong","year":"2013","unstructured":"Gong IY, Kim RB (2013) Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol England 29:S24-33","journal-title":"Can J Cardiol England"},{"key":"4556_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.18773\/austprescr.2019.039","volume":"42","author":"H Stevens","year":"2019","unstructured":"Stevens H, Tran H, Gibbs H (2019) Venous thromboembolism: current management. Aust Prescr Australia 42:123\u2013126","journal-title":"Aust Prescr Australia"},{"key":"4556_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","volume":"394","author":"LA Castellucci","year":"2026","unstructured":"Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, C\u00f4t\u00e9 B, Schulman S, de Wit K, Douketis J, Suryanarayan D, Wan T, Yeo E, Le Templier G, Tran HA, Willcox A, Crowther HJ, Prasad R, Shivakumar S, Umana E et al (2026) Bleeding risk with Apixaban vs. Rivaroxaban in acute venous thromboembolism. N Engl J Med 394:1051\u20131060","journal-title":"N Engl J Med"},{"key":"4556_CR29","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:372","journal-title":"BMJ"},{"key":"4556_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-319-93791-5_2","volume":"1082","author":"BKC Chan","year":"2018","unstructured":"Chan BKC (2018) Data analysis using R programming. Adv Exp Med Biol United States 1082:47\u2013122","journal-title":"Adv Exp Med Biol United States"},{"key":"4556_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jclinepi.2020.09.018","volume":"129","author":"JL Brozek","year":"2021","unstructured":"Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, Cronin M, Djulbegovic B, Falavigna M, Guyatt GH, Gordon AA, Hilton Boon M, Hutubessy RCW, Joore MA, Katikireddi V, LaKind J, Langendam M, Manja V, Magnuson K, Mathioudakis AG et al (2021) GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-an overview in the context of health decision-making. J Clin Epidemiol United States 129:138\u2013150","journal-title":"J Clin Epidemiol United States"},{"key":"4556_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamainternmed.2025.1109","volume":"185","author":"S Bea","year":"2025","unstructured":"Bea S, Iyer GS, Kim DH, Lin KJ, Zhang Y, Zakoul H, Tesfaye H, Bykov K (2025) Oral anticoagulation and risk of adverse clinical outcomes in venous thromboembolism. JAMA Intern Med 185:837\u2013846","journal-title":"JAMA Intern Med"},{"key":"4556_CR33","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/jth.15799","volume":"20","author":"T Fukasawa","year":"2022","unstructured":"Fukasawa T, Seki T, Nakashima M, Kawakami K (2022) Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: a cohort study. J Thromb Haemost Elsevier Masson SAS 20:2083\u20132097","journal-title":"J Thromb Haemost Elsevier Masson SAS"},{"key":"4556_CR34","doi-asserted-by":"publisher","first-page":"106438","DOI":"10.1016\/j.ejim.2025.106438","volume":"142","author":"M Roupe","year":"2025","unstructured":"Roupe M, Rosengren A, Pivodic A, Bertilsson R, Philipson J, Svennerholm K, Tavoly M, Glise Sandblad K (2025) Bleeding risk on rivaroxaban versus apixaban in older patients with venous thromboembolism: a nationwide observational register-based study. Eur J Intern Med 142:106438","journal-title":"Eur J Intern Med"},{"key":"4556_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/ehjcvp\/pvy021","volume":"4","author":"C Sindet-Pedersen","year":"2018","unstructured":"Sindet-Pedersen C, Staerk L, Pallisgaard JL, Gerds TA, Berger JS, Torp-Pedersen C, Gislason GH, Olesen JB (2018) Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. Eur Heart J Cardiovasc Pharmacother 4:220\u2013227","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4556_CR36","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.mayocp.2018.09.022","volume":"94","author":"DM Bott-Kitslaar","year":"2019","unstructured":"Bott-Kitslaar DM, McBane RD, Casanegra AI, Houghton DE, Froehling DA, Vlazny DT, Ashrani AA, Hodge DO, Vargas ER, Bartlett MA, Saadiq RA, Daniels PR, Shields RC, Lenz CJ, Lang TR, Wysokinski WE (2019) Apixaban and Rivaroxaban in patients with acute venous thromboembolism. Mayo Clin Proc Mayo Found Med Educ Res 94:1242\u20131252","journal-title":"Mayo Clin Proc Mayo Found Med Educ Res"},{"key":"4556_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1177\/0897190017722873","volume":"31","author":"DO Davis","year":"2018","unstructured":"Davis DO, Davis KA (2018) Evaluation of direct-acting oral anticoagulant use in patients with cancer. J Pharm Pract 31:441\u2013444","journal-title":"J Pharm Pract"},{"key":"4556_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/M21-0717","volume":"175","author":"GK Dawwas","year":"2022","unstructured":"Dawwas GK, Leonard CE, Lewis JD, Cuker A (2022) Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med 175:20\u201328","journal-title":"Ann Intern Med"},{"key":"4556_CR39","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.tru.2022.100121","volume":"9","author":"R Halder","year":"2022","unstructured":"Halder R, Brucks E, Cheng C, Saboda K, Babiker HM, Mcbride A, Recio-Boiles A (2022) Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation. Thromb Updat 9:100121","journal-title":"Thromb Updat"},{"key":"4556_CR40","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","volume":"6","author":"M Kushnir","year":"2019","unstructured":"Kushnir M, Choi Y, Eisenberg R, Rao D, Tolu S, Gao J, Mowrey W, Billett HH (2019) Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol Elsevier Ltd 6:e359\u2013e365","journal-title":"Lancet Haematol Elsevier Ltd"},{"key":"4556_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.thromres.2020.06.035","volume":"193","author":"J Trujillo-Santos","year":"2020","unstructured":"Trujillo-Santos J, Beroiz P, Moustafa F, Alonso A, Morejon E, L\u00f3pez-Reyes R, Casado I, Porras JA, Flores K, L\u00f3pez-N\u00fa\u00f1ez JJ, Monreal M (2020) Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thromb Res Elsevier Ltd 193:160\u2013165","journal-title":"Thromb Res Elsevier Ltd"},{"key":"4556_CR42","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/ajh.25604","volume":"94","author":"WE Wysokinski","year":"2019","unstructured":"Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott-Kitslaar DM, Froehling DA, Hodge DO, Peterson LG, Mcbane RD (2019) Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol 94:1185\u20131192","journal-title":"Am J Hematol"},{"key":"4556_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.thromres.2020.06.035","volume":"193","author":"J Trujillo-Santos","year":"2020","unstructured":"Trujillo-Santos J, Beroiz P, Moustafa F, Alonso A, Morejon E, L\u00f3pez-Reyes R, Casado I, Porras JA, Flores K, L\u00f3pez-N\u00fa\u00f1ez JJ, Monreal M (2020) Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thromb Res United States 193:160\u2013165","journal-title":"Thromb Res United States"},{"key":"4556_CR44","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a Clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet Switzerland 58:1265\u20131279","journal-title":"Clin Pharmacokinet Switzerland"},{"key":"4556_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/PPA.S82484","volume":"10","author":"F Fabbian","year":"2016","unstructured":"Fabbian F, De Giorgi A, Tiseo R, Zucchi B, Manfredini R (2016) Reducing the risk of venous thromboembolism using apixaban - patient perspectives and considerations. Should more attention be given to females? Patient Prefer Adherence 10:73\u201380","journal-title":"Patient Prefer Adherence"},{"key":"4556_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11239-023-02926-3","volume":"57","author":"D Fredman","year":"2024","unstructured":"Fredman D, McNeil R, Eldar O, Leader A, Gafter-Gvili A, Avni T (2024) Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: a systematic review and meta-analysis of observational studies. J Thromb Thrombolysis Netherlands 57:453\u2013465","journal-title":"J Thromb Thrombolysis Netherlands"},{"key":"4556_CR47","first-page":"54","volume":"2019","author":"SV Konstantinides","year":"2019","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, Huisman MV, Humbert M, Jennings CS, Jim\u00e9nez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, \u00c1inle FN, Prandoni P, Pruszczyk P, Righini M et al (2019) ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European society o. Eur Respir J England 2019:54","journal-title":"Eur Respir J England"},{"key":"4556_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2025.100220","volume":"20","author":"LS Vest","year":"2025","unstructured":"Vest LS, Baik SH, Baye F, Fung K-W, McDonald CJ (2025) Hospitalizations for bleeding associated with apixaban versus rivaroxaban according to dose in Medicare beneficiaries. Thromb Update 20:100220","journal-title":"Thromb Update"},{"key":"4556_CR49","doi-asserted-by":"publisher","first-page":"101673","DOI":"10.1016\/j.jsps.2023.06.006","volume":"31","author":"MS Al Yami","year":"2023","unstructured":"Al Yami MS, Qudayr AH, Alhushan LM, Hakami FM, Korayem GB, Alshaya OA, Almohammed OA (2023) Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: a multi-center retrospective observational study. Saudi Pharm J 31:101673","journal-title":"Saudi Pharm J"},{"key":"4556_CR50","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an oral factor Xa inhibitor with low molecular weight Heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol Off J Am Soc Clin Oncol United States 36:2017\u20132023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol United States"},{"key":"4556_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost England 18:411\u2013421","journal-title":"J Thromb Haemost England"},{"key":"4556_CR52","first-page":"1174","volume":"55","author":"HA Tran","year":"2025","unstructured":"Tran HA, Merriman E, Baker R, Curnow J, Young L, Tan CW, McRae S, Chunilal SD (2025) 2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management. Intern Med J Australia 55:1174\u20131183","journal-title":"Intern Med J Australia"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04556-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04556-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04556-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:57Z","timestamp":1791572517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04556-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":52,"alternative-id":["4556"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04556-y","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval and consent to participate were needed.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}